Jill E Brown
MD, MPH, MHS
EducationDuke University School of Medicine, Masters in Health Sciences in Clinical Research
Tufts University School of Medicine, M.D., Masters of Public Health
University of Pennsylvania, B.A.
BiographyDr. Brown trained in Obstetrics & Gynecology at the Uniformed Services Residency in Obstetrics & Gynecology from 2001 to 2005. She then served as a staff Obstetrician/Gynecologist in the US Navy from 2005 to 2009. Dr. Brown then transitioned to the Public Health Service and worked at the FDA performing pre-market review for OBGYN devices from 2009 to 2012. She then moved to NIAID where she was the medical officer for the Sexually Transmitted Diseases Branch from 2012 to 2017. From 2017 to 2021, she served as the medical officer for the Contraceptive Development Program at NICHD. In 2021, Dr. Brown retired from the Public Health Service and joined the faculty at USUHS.
Career Highlights: Positions, Projects, Deployements, Awards and Additional Publications
Thirty-day deployment for USPHS Operation Artemis mission to support reunification of unaccompanied minors with sponsors in the United States. Served as USPHS Officer in Charge and Department of Health and Human Services Chief Medical Officer. Pomona, CA
Thirty-day deployment to aid in COVID-19 response and augment Obstetrics department in Navajo Nation. Shiprock, NM
Fourteen-day deployment to augment Service Access Team at Atlanta Federal Coordinating Center, assisted with coordination of care and disposition of 324 medical evacuees from Hurricane Maria. Served as Deputy Team Lead for 5 days. Atlanta, GA
Thirty-day deployment in support of critical need at Rosebud Indian Health Hospital to assist with Obstetrics Department policies and systems and to provide obstetrics clinical support. Rosebud, SD
Hubacher D, Schreiber CA, Turok DK, Jensen JT, Creinin MD, Nanda K, White KO, Dayananda I, Teal SB, Chen PL, Chen BA, Goldberg AB, Kerns JL, Dart C, Nelson AL, Thomas MA, Archer DF, Brown JE, Castaño PM, Burke AE, Kaneshiro B, Blithe DL. Continuation rates of two different-sized copper intrauterine devices among nulliparous women: Interim 12-month results of a single-blind, randomised, multicentre trial. EClinicalMedicine. 2022 Sep;51:101554. doi: 10.1016/j.eclinm.2022.101554.
Jacobsohn T, Nguyen BT, Brown JE, Thirumalai A, Massone M, Page ST, Wang C, Kroopnick J, Blithe DL. Male Contraception is Coming: Who Do Men Want to Prescribe their Birth Control? Contraception, 2022. Advance online publication. https://doi.org/10.1016/j.contraception.2022.04.014.
Westhoff CL, Archer DF, Barnhart K, Darney P, Gilliam M, Jensen J, Nelson A, Teal S, Thomas M, Hu J, Brown J, Blithe DL. Evaluation of ovulation and safety outcomes in a multi-center randomized trial of three 84-day ulipristal acetate regimens. Contraception, 2022. Apr 14:S0010-7824(22)00107-X. doi: 10.1016/j.contraception.2022.04.002. Epub ahead of print. PMID: 35430238.
Nguyen BT, Yuen F, Farrant M, Thirumalai A, Fernando F, Amory JK, Swerdloff RS, Anawalt BD, Blithe DL, Long JE, Liu PY, Page ST, Wang C. Acceptability of the oral hormonal male contraceptive prototype, 11beta-methyl-19-nortestosterone dodecylcarbonate (11beta-MNTDC), in a 28-day placebo-controlled trial. Contraception, 2021. https://doi.org/10.1016/j.contraception.2021.06.009.
Long JE, Lee MS, PhD, Blithe DL. Update on novel hormonal and non-hormonal male contraceptive development. The Journal of Clinical Endocrinology & Metabolism, 2021; dgab034, https://doi.org/10.1210/clinem/dgab034.
Thirumalai A, Yuen F, Amory JK, Hoofnagle AN, Swerdloff RS, Liu PY, Long JE, Blithe DL, Wang C, Page ST. Dimethandrolone Undecanoate, a Novel, Nonaromatizable Androgen, Increases P1NP in Healthy Men Over 28 Days. J Clin Endocrinol Metab. 2021 Jan 1;106(1):e171-e181. doi: 10.1210/clinem/dgaa761. PMID: 33090208; PMCID: PMC7765650.
Chen MJ, Creinin MD, Turok DK, Archer DF, Barnhart KT, Westhoff CL, Thomas MA, Jensen JT, Variano B, Sitruk-Ware R, Shanker A, Long J, Blithe DL. Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate [published online ahead of print, 2020 May 13]. Contraception. 2020;S0010-7824(20)30152-9. PMID: 32416145 DOI: 10.1016/j.contraception.
Yuen F, Thirumalai A, Pham C, Swerdloff R, Anawalt B, Liu P, Amory J, Bremner W, Dart C, Wu H, Hull L, Blithe D, Long J, Wang C, Page S, Daily Oral Administration of the Novel Androgen 11beta-MNTDC Markedly Suppresses Serum Gonadotropins In Healthy Men. The Journal of Clinical Endocrinology & Metabolism. Volume 105, Issue 3, March 2020. PMID: 31976519 DOI: 10.1210/clinem/dgaa032.
Taylor SN, Marrazzo J, Batteiger BE, Hook EW 3rd, Seña AC, Long J, Wierzbicki MR, Kwak H, Johnson SM, Lawrence K, Mueller J. Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea. N Engl J Med. 2018 Nov 8;379(19):1835-1845. PMID: 30403954 DOI: 10.1056/NEJMoa1706988.
Long J, Wierzbicki M, Hook E. Impact of Eligibility Criteria on Participant Enrollment for a Randomized Clinical Trial of Gonorrhea Treatment. Sexually Transmitted Diseases. 2017 Jun; 44(6):362-364. PMID: 28499287 PMCID: PMC5431289.